Home Biosimilar Antibodies Immunology & Inflammation Immunology & Inflammation related Ligelizumab (Anti-IgE)
For research use only. Not for use in humans.

Ligelizumab (Anti-IgE)

Synonyms: Immunoglobulin Epsilon， Ig Epsilon Chain C Region

Ligelizumab (anti-IgE) is a humanized high-affinity monoclonal anti-IgE antibody with the potential to be used in research on chronic spontaneous urticarial. MW: 146.6 KD.

Ligelizumab (Anti-IgE)

Quality Control

  • Cited in Nature Medicine for its top-tier quality
  • SDS
  • Datasheet
99

Specificity

Expand to Check More
1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description
Ligelizumab (anti-IgE) is a humanized high-affinity monoclonal anti-IgE antibody with the potential to be used in research on chronic spontaneous urticarial. MW: 146.6 KD.
References

Product Details

CAS No. 1322627-61-1
Molecular Weight 146.6
Isotype Human IgG1
Source CHO
Purification AKTA
Sterility 0.2 μM filtered
Formulation 100 mM Pro-Ac, 20mM Arg, pH5.0
Storage
(From the date of receipt)		 Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT05678959 TERMINATED Drug: Ligelizumab 120 mg|Drug: Ligelizumab 240 mg Food Allergy Novartis Pharmaceuticals 2023-04-27 PHASE3
NCT04984876 TERMINATED Drug: ligelizumab|Drug: Placebo Allergy, Peanut Novartis Pharmaceuticals 2021-12-07 PHASE3
NCT04210843 TERMINATED Drug: Ligelizumab Chronic Spontaneous Urticaria Novartis Pharmaceuticals 2020-04-08 PHASE3
NCT05024058 TERMINATED Drug: Ligelizumab Chronic Inducible Urticaria Novartis Pharmaceuticals 2021-11-16 PHASE3
NCT04513548 TERMINATED Drug: Ligelizumab|Drug: Placebo Chronic Spontaneous Urticaria; Cholinergic Urticaria; Cold Urticaria Novartis Pharmaceuticals 2020-08-05 PHASE1
NCT03907878 COMPLETED Chronic Spontaneous Urticaria Novartis Pharmaceuticals 2019-04-13 PHASE3

(data from https://clinicaltrials.gov, updated on 2026-01-13)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.